Brief: Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted To BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency (AATD)
29/05/2025 21:05
May 29 (Reuters) - Beam Therapeutics Inc BEAM.O: BEAM THERAPEUTICS ANNOUNCES U.S. FDA ORPHAN DRUG DESIGNATION GRANTED TO BEAM-302 FOR THE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) BEAM THERAPEUTICS INC - INITIATES DOSING IN FOURTH COHORT, DATA EXPECTED IN H2 2025 BEAM THERAPEUTICS INC - TO DOSE FIRST PATIENT IN PART B OF TRIAL IN H2 2025 Source text: ID:nGNXc1V0Xw Further company coverage: BEAM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beam Therapeutics
See all newsBeam Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Beam Therapeutics Q1 net loss narrows beating analyst estimates
U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas
U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta